

Symptomatic Relief of Botulinum Neurotoxin/ A Intoxication with Aminopyridines: A New Twist on an Old Molecule

Alexander V. Mayorov[†], Bert Willis[†], Antonia Di Mola[†], Derek Adler[‡], Jennifer Borgia[‡], Olin Jackson[‡], Jie Wang[‡], Yongyi Luo[‡], Lei Tang[‡], Richard J. Knapp[‡], Chandra Natarajan[‡], Michael C. Goodnough[§], Noam Zilberberg^{||}, Lance L. Simpson[⊥], and Kim D. Janda^{†,*}

[†]Departments of Chemistry and Immunology, Skaggs Institute for Chemical Biology and Worm Institute of Research & Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States,

[‡]Sanofi-Aventis, Discovery Metabolism and Pharmacokinetics Safety Department, Bridgewater, New Jersey 08807, United States, [§]Metabiologics, 505 South Rosa Road, Madison, Wisconsin 53719, United States, ^{||}Department of Life Sciences, Ben Gurion University, Beer Sheva 84105, Israel, and [⊥]Department of Medicine Jefferson Medical College, Thomas Jefferson University, 1020 Locust St, Rm 314-JAH, Philadelphia, Pennsylvania 19107, United States

Botulinum neurotoxins (BoNTs A–G) are a family of seven immunologically distinct proteins derived from strains of *Clostridium botulinum*, a Gram-positive, sporulating anaerobic bacillus (1). Botulinum neurotoxins are responsible for botulism, a disease historically associated with food poisoning. Furthermore, the BoNTs are also some of the most deadly toxins known to man, approximately 10 million times more deadly than cyanide (2), and are characterized by peripheral neuromuscular blockade and a characteristic flaccid paralysis.

The BoNTs potent toxicity coupled with their highly specific mechanism of action render these neurotoxins both useful to medicine and a public threat. Indeed, the BoNTs are classified by the US Centers for Disease Control (CDC) as bioterrorism agents due to a relative ease of production, their extreme lethal potency (1 ng kg⁻¹) (3), and the duration of their paralytic activity. With the current concerns of biological warfare around the world, a vastly enhanced defense against potential bioterrorist weapons is of high priority (4, 5). Currently, there are no approved pharmacological treatments for BoNT intoxication (6). We also note that due to the protracted paralysis and necessity for intubation and mechanical respiration, the numbers of medical care units capable of providing supportive care for recovery in the event of a bioterrorism incident would be limited.

Botulinum toxins induce muscle paralysis through inhibition of acetylcholine release at neuromuscular junc-

ABSTRACT Botulinum neurotoxins (BoNT) are the etiological agents responsible for botulism, a disease characterized by peripheral neuromuscular blockade and a characteristic flaccid paralysis of humans. BoNT/A is the most toxic protein known to man and has been classified by the Centers of Disease Control (CDC) as one of the six highest-risk threat agents for bioterrorism. Of particular concern is the apparent lack of clinical interventions that can reverse cellular intoxication. Efforts to uncover molecules that can act within an intoxicated cell so as to provide symptomatic relief to BoNT/A are paramount. Aminopyridines have shown clinical efficacy for multiple sclerosis treatment as well as BoNT/A intoxication; yet, aminopyridines for BoNT/A treatment has been abandoned because of blood brain barrier (BBB) penetration producing undesired neurotoxic side effects. Two aminopyridines (5 and 11) exhibited inhibitory activity toward *Shaker*-IR voltage-gated potassium (K_v1.x) channels with potencies similar to that of the previous “gold-standard”, 3,4-diaminopyridine (3,4-DAP), including reversal of symptoms from BoNT-induced paralysis in phrenic nerve-hemidiaphragm preparations. Importantly, pharmacokinetic experiments revealed a lack of BBB penetration of 5, which is a significant advancement toward resolving the neurotoxicity issues associated with prolonged 3,4-DAP treatments. Finally, 5 was found to be as effective as 3,4-DAP in rescuing BoNT-poisoned mice in the mouse lethality assay, signifying an optimized balance between the undesired permeability across the BBB and the required permeability across lipid cellular membranes. The results demonstrate that 5 is the most promising small molecule K⁺ channel inhibitor discovered to date for the treatment of BoNT/A intoxication.

*Corresponding author,
kdjanda@scripps.edu.

Received for review March 26, 2010
and accepted October 11, 2010.

Published online October 11, 2010

10.1021/cb1002366

© 2010 American Chemical Society




Figure 1. Structures of the leading small molecule K⁺ channel inhibitors 1–3 and the experimental analogues 4–12.

tions by proteolytic cleavage of SNARE (soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor) proteins (7, 8). This effect can be reduced or reversed by enhancing phasic Ca²⁺ influx by blocking voltage-dependent K⁺ channels in nerve terminals, allowing acetylcholine release within the synaptic cleft. To our knowledge, only a handful of compounds, including TEA (tetraethylammonium) **1** (9–11), 4-aminopyridine (4-AP) **2** (12, 13), and 3,4-diaminopyridine (3,4-DAP) **3** (13) (Figure 1), have been shown to act as reversible K⁺ channel blockers with an ability to allow synaptic response recovery from serotype A BoNT poisoning, generating a muscle action potential and inducing muscle contraction *in vitro* and in animal models. It is important to note that prior literature reports include conflicting and often puzzling accounts of clinical treatment of patients suffering severe serotype A and B BoNT intoxications with 3,4-DAP. Intriguingly 3,4-DAP was reportedly effective in treatment of BoNT/B poisoning (14) but, even more puzzling, failed to provide symptomatic relief to BoNT/A-intoxicated patients (15). One possible explanation for the apparent inconsistency is the low tolerance of the patients to high doses of 3,4-DAP, which are necessary for effective restoration of muscle function (16).

Interestingly, these aminopyridines have also been considered as therapeutics for symptomatic treatment of such neurological disorders as myasthenia gravis (17), multiple sclerosis (18), spinal cord injuries (19), and Alzheimer's disease (20), providing an additional incentive for further exploration of the aminopyridine template. Yet, while 4-AP and 3,4-DAP have produced

impressive results as potential therapeutics, they also have presented certain toxicity issues. Seizures have been reported previously with these aminopyridines that arise from their penetration across the blood-brain barrier (BBB). Discovery of molecules that could obviate BBB crossing while still bringing synaptic relief in the form of a rapid, albeit temporary, reversal of paralysis could provide inroads to an alternative form of care for BoNT intoxication.

Among aminopyridines previously tested for K⁺ channel antagonism and subsequent reversal of BoNT/A-induced paralysis, 3,4-DAP was found to be highly effective while possessing the least toxicity (13). The observed central nervous system (CNS) toxicity of 3,4-DAP has been associated with its ability to cross the BBB (21–23), and lipid membranes in general, while in its neutral form, which in turn is requisite for its efficacy in blocking K⁺ channels. An attempt to reduce lipid membrane penetrability by generating a cationic quaternary analogue of 3,4-DAP produced 3,4-diamino-1-methylpyridinium **4** (Figure 1); unfortunately, **4** was determined to be inactive in rat phrenic nerve-hemidiaphragm preparations. This latter result led a leading botulinum research group in the mid-1990s to state that “it does not appear possible to produce structural modifications of 3,4-DAP that would completely eliminate its CNS toxicity” (13). However, ample crystallographic and modeling literature data has been amassed to challenge this assertion (24–26), which we saw as an opportunity to discover new molecules, potentially with an improved therapeutic index.

In the context of K⁺ channel modulation, a substantial body of experimental (27, 28) and theoretical (24–26) evidence indicates that aminopyridine pharmacophore requirements include a positive charge, usually a result of protonation, and at least one amino group suitable for hydrogen bonding. Observations of pH dependence of aminopyridine activity (28), as well as modeling reports (24–26), indicate that aminopyridines cross cellular membranes in their neutral form and then are reionized and block K⁺ channels from the intracellular side of the pore. Docking simulations suggest that protonated aminopyridines form several hydrogen bonds with the amide group oxygen atoms of the four Thr¹⁰⁷ and Ala¹¹¹ residues located on separate chains of the tetrameric assembly composed of four K⁺ channel α -subunits, while orienting the molecular plane of the ligand perpendicular to the axis of the pore, thus effec-

tively blocking it (29). Thus, manipulations of the 3,4-DAP structure, affecting its pK_a and the predisposition for hydrogen bonding seemed viable as a route toward aminopyridine analogues with improved BoNT/A-induced paralysis-alleviating activity, while using the same technique to simultaneously reduce the transient brain penetration, which is responsible for the neurotoxicity of 3,4-DAP.

RESULTS AND DISCUSSION

Conceptual Design of Aminopyridine Analogues.

3,4,5-Triaminopyridine **5**, preparation was contemplated to test the effects of augmented hydrogen bonding as well as the potential influence of enhancement of basicity of the pyridine moiety. The pK_a values of 4-aminopyridine, 3,4-diaminopyridine, and 3,4,5-triaminopyridine were estimated to be 9.2, 8.9, and 8.8, respectively (see Supporting Information for details), which is in a reasonable agreement with the experimental pK_a value of 4-aminopyridine reported at 9.114 (30). While the differences among the pK_a values of these compounds are relatively small, they may influence not only the interaction with K_v channels but also the rate of intracellular penetration, thus affecting their therapeutic values. We also surmised that the reduced lipophilicity would result in decreased brain penetration and diminished neurotoxicity compared to 3,4-DAP.

N-Alkylation of the 4-amino group (3-amino-4-(dimethylamino)pyridine **6**) was anticipated to result in deconjugation of that group from the pyridine moiety due to steric effects, allowing investigations into the significance of electronic effects of 4-amino group as well as to probe the ramifications of the *N*-alkylation on hydrogen bonding interactions with the K^+ channel. In contrast, rigidified 5-azabenzimidazole **7** was projected to force full conjugation of both amino groups with the pyridine moiety, potentially affecting the hydrogen bonding pattern during the K^+ channel binding, and to amplify π -cation and π - π interactions, which are responsible for the binding of aminopyridines to the receptor site in the K^+ channel, as suggested by literature reports (25). *N*-Oxide analogues **8** and **9** would be prepared, as they are readily accessible, are highly polar molecules, and have excellent water solubility, and the N-O moiety of pyridine *N*-oxides possesses unique chemical/biological functionality, which can act effectively as a push electron donor and as a pull electron acceptor group. The pyrido[4,3-*b*]piperazine analogue **10**

was of interest as it possesses a somewhat less rigid scaffold than that of azabenzimidazole **7**, while maintaining the conjugation of the amino groups with the pyridine moiety. The 3,4-diamino-1-(prop-2-ynyl)pyridinium analogue **11** was to be prepared and tested to assess the previously held view that pyridinium salts cannot effectively function as K^+ channel blockers (13). Importantly, this compound, should the prior held tenet be proven incorrect, could serve as a second molecular scaffold for aminopyridinium structures using the Huisgen 1,3-dipolar reaction or, as it has been popularized and retermed by Sharpless, the “click” reaction, which is an ideal method to install diversity within a library, especially one biologically based in nature (31). Finally, modification of TEA **1** *via* introduction of an aromatic moiety would permit examination of potentially crucial π - π interactions found within the receptor combining site; such interactions could be explored through triethyl-3-phenylpropylammonium **12**.

Chemistry. Analogues **5**–**12** (Figure 1) were synthesized using modified procedures from the corresponding literature reports (Supporting Information, S3–S5). Thus, nitration of 4-aminopyridine and *N,N*-dimethyl-4-aminopyridine followed by catalytic hydrogenation of the nitro-intermediates yielded 3,4,5-triaminopyridine **5** (32) and 3-amino-4-(dimethylamino)pyridine **6** (33), respectively. 5-Azabenzimidazole **7** was used as commercially available, and the corresponding *N*-oxide **9** was prepared by Re^V -mediated hydrogen peroxide oxidation (34) of **7**. Compound **8** was synthesized by amination of 3-bromo-4-nitropyridine-1-oxide (35) with dimethylamine (36, 37), and the subsequent catalytic hydrogenation of the product. Stepwise reductive amination of glyoxal with 3,4-diaminopyridine **3** produced pyrido[4,3-*b*]piperazine **10** (38). The 3,4-diamino-1-(prop-2-ynyl)pyridinium analogue **11** and triethyl-3-phenylpropylammonium compound **12** were obtained by *N*-alkylations of 3,4-diaminopyridine **3** with propargyl bromide and of triethylamine with (3-bromopropyl)benzene, respectively.

Mouse Phrenic Nerve-Hemidiaphragm Assay. With a series of molecules in hand, their efficacy was initially queried in the reversal of BoNT/A-induced paralysis using mouse phrenic nerve-hemidiaphragm preparations. Since BoNT markedly alters evoked transmitter release at neuromuscular junctions, the hemidiaphragm assay is an ideal technique to examine agents that can modulate nerve activity (39). Under this semblance we consid-

TABLE 1. Paralysis times (min) at 10 pM BoNT/A^a

	0 μ M	30 μ M	100 μ M	330 μ M
Control	102 \pm 6			
3 (3,4-DAP)		110 \pm 6	303 \pm 14	408 \pm 23
5		108 \pm 6	230 \pm 19	304 \pm 15
6		107 \pm 7	223 \pm 17	285 \pm 12
10		104 \pm 9	200 \pm 21	243 \pm 19
11		106 \pm 4	207 \pm 10	332 \pm 6

^aParalysis is defined as a 90% reduction in twitch amplitude. The data represents the mean \pm SE ($n = 10$).

ered two complementary routes to examine our molecules: the first involved measurement of reduced *in vivo* BoNT lethality, and the second would measure a compound's effect in delaying the onset and slowing the progression of paralysis, which is a well-characterized model that has been used to benchmark 4-AP and 3,4-DAP in the past (40). At 330 μ M, the compounds **5**, **6**, and **10** exhibited potencies slightly lower than that of 3,4-DAP, with the differences found to be statistically significant at the 0.05 level (2-tailed tests), whereas at the lower concentrations the differences became negligible. As evident from Table 1, 3,4,5-triaminopyridine **5** was found to be quite potent in comparison to the benchmark compound 3,4-DAP, which can be rationalized by augmented hydrogen bonding between ligand and the K⁺ channel receptor site, as well as essentially the same pK_a with respect to 3,4-DAP. *N*-Methylation of the 4-amino group (analogue **6**) resulted in a slight decline in efficacy compared to 3,4-DAP, possibly due to steric interference from the *N*-methyl groups, as well as a diminished pK_a of the pyridine moiety, which was estimated to be 8.2. Azabenzimidazole **7** and the *N*-oxide compounds **8** and **9** were found to be unable to reverse BoNT/A-induced muscle paralysis, likely due to steric hindrance of the amino groups thus weakening the requisite hydrogen bonding with the K⁺ channel receptor site, as well as the possibly low tolerance of the receptor for the modification of the pyridine moiety *via N*-oxidation. The pyrido[4,3-*b*]piperazine analogue **10** was determined to possess a modest potency in this assay, indicating a limited benefit from *N*-alkylation of the 3- and 4-amino groups of the 3,4-DAP template in the search for potent K⁺ channel blockers. The 3,4-diamino-

1-(prop-2-ynyl)pyridinium analogue **11**, on the other hand, demonstrated a high efficacy in paralysis reversal, statistically indistinguishable from that of 3,4-DAP, in sharp contrast with the previously reported inactive *N*-methylpyridinium, **4**. It seems plausible that the analogue **11** benefits from the increased hydrophobicity of the *N*-propynyl group, compared to the *N*-methyl analogue **4**, which facilitates the transport of this compound through cellular membranes, with the increased steric bulk of the *N*-alkyl group having little or no effect on this analogue's potency. Finally, the apparent neurotoxicity of the compound **12** prevented determination of its ability to reverse BoNT/A-induced muscle paralysis.

From the phrenic nerve-hemidiaphragm results there are several key points, the most salient being that there is a window of opportunity to find new aminopyridines that can be of therapeutic interest. Of further importance is that both substitution on the aminopyridine ring and pyridinium salts are viable options. The latter discovery is especially exciting as previously it was disclosed (*vide supra*) that such structures were not thought to be feasible for treating BoNT intoxication (13). Finally, we note that pyridines **5** and **11** at first glance appear not as potent as 3,4-DAP (Table 1); however, if we compare apparent toxicity (Table 2) for all three compounds at 3.3×10^{-4} M, where the toxin's time to paralysis becomes in essence equally attenuated, these compounds become equivalent to each other with respect to therapeutic value.

Electrophysiological Studies. The biological effects of the leading aminopyridines **5** and **11** as well as the 3,4-DAP **3** control were investigated in *X. laevis* oocytes

TABLE 2. Apparent toxicity (%) at 10 pM BoNT/A^a

	0 μ M	30 μ M	100 μ M	330 μ M
Control	100			
3 (3,4-DAP)		99	9	6
5		99	10	9
11		99	20	8

^aApparent toxicity = percent of toxicity (as measured by paralysis time) of tissues exposed to 10 pM BoNT/A, *e.g.*, 10% toxicity is equivalent to the toxicity of a 1 pM BoNT/A dose.




Figure 2. Dose–response curves for inhibition of *Shaker* channels by 3,4-DAP, 5, and 11. The data represents the mean \pm SE ($n = 5$).

heterologously expressing *Shaker*-IR K_v channel variant (41, 42) using the two-electrode voltage clamp (TEVC) technique (43). The IC_{50} values for the compounds **3**, **5**, and **11** were determined to be 22.2, 697, and 26.7 μM , respectively (Figure 2). These findings unambiguously show that the aminopyridines **5** and **11** are inhibitors of $K_v1.x$ channels, with the potencies comparable to that of 3,4-DAP. This result also correlates well with the results from the BoNT-induced paralysis reversal in phrenic nerve-hemidiaphragm preparations, where 3,4-DAP **3** exhibited the highest potency and compounds **5** and **11** compounds had similar, albeit slightly lower efficacy. The lower potency of **5** compared to that of 3,4-DAP is likely to be a reflection of the different sensitivity of rat neuronal channels and *Drosophila Shaker* channels and, perhaps, in part due to complexity of the expression pattern of K_v channels in the nervous system.

Pharmacokinetics and Mouse Brain Penetration after ip Injection. Since the neurotoxic side effects of 3,4-DAP had been attributed to its transient brain penetration, it was imperative to retain the inhibitory potency of 3,4-DAP toward K^+ channels but also to limit its brain exposure. The earlier literature reports noted that 3,4-DAP exhibited somewhat less brain penetration than 4-aminopyridine, probably due to reduced lipophilicity, as well as the increased propensity toward hydrogen bonding (21, 22, 44). It therefore seemed plausible that introduction of additional hydrogen bond donor or acceptor groups into 3,4-DAP (3,4,5-triaminopyridine **5**) or its *N*-alkylation (yielding the cationic compound **11**)

would result in the desired reduction in brain exposure. The pharmacokinetics results for the tested compounds **3**, **5**, and **11** showed rapid absorption into the plasma from the ip site of injection with the T_{max} occurring at 0.50 h (first time point collected) for all three compounds (Figure 3). The plasma half-lives for **5** and **3** (3,4-DAP) of 0.31 and 0.34 h, respectively, are quite short and would have produced little accumulation in plasma, while the plasma half-life of **11**, determined to be 1.2 h, was long enough to pro-

duce some plasma accumulation under the repeat dose regimen necessary for an effective reversal of BoNT-induced paralysis. Compound **11** produced the highest plasma exposure with a C_{max} of 402 ng mL^{-1} and an $AUC(0\text{-infinity})$ of 620 $\text{h}\cdot\text{ng mL}^{-1}$, with a low brain exposure that was 13% of the plasma exposure. At the same time, triaminopyridine **5** gave both the lowest plasma exposure and no detectable brain exposure at 3.0 mg kg^{-1} ip, although the possibility of a significant brain exposure at a higher dose cannot be eliminated at this point. The control compound **3** (3,4-DAP) with a brain to plasma ratio of 0.38 showed significant brain penetration, which seems to correlate with the literature reports (21, 22).

Mouse Lethality Assay. To further examine the therapeutic relevance of these compounds, a mouse lethality assay was carried out. The mouse toxin neutralization uses death as an end point and is the only animal model approved for the study of antagonists with botulinum neurotoxins. The importance of this experiment is that the results obtained will show definitively whether a molecule can provide symptomatic relief from BoNT/A intoxication. Initially, both leading compounds **5** and **11** were examined for toxicity issues by administering 200 μg of each compound and observing the animals over a 48 h period; no distress was observed at this dose level. The rescue experiments were conducted at 10 LD_{50} 's of BoNT/A ($n = 10$) for both the control (BoNT/A alone) and animals that were to be treated with **5**, **11**, or 3,4-DAP. An arbitrary dose of 75 μg of each aminopyridine compound was used, as this dose




Figure 3. Concentration (ng mL^{-1}) of substrate in mouse plasma and brain tissue after ip administration of 3,4-DAP and analogues **5** and **11** at 3.0 mg kg^{-1} (nonserial sampling). The data represents the mean \pm SE ($n = 3$).

of 3,4-DAP was shown to relieve the effects of BoNT/A poisoning. At 120 min first signs of BoNT distress was observed, and **5**, **11**, or 3,4-DAP was administered ip. Subsequently, every 75 min each of these compounds

were administered for a total of 5 injections; the results are shown in Figure 4. Remarkably, 3,4,5-triaminopyridine **5** was found to be as effective as 3,4-DAP, whereas 3,4-diamino-1-(prop-2-ynyl)pyridinium **11** was not. At this juncture the reason for the observed low efficacy of **11** remains unclear; however, we surmise that metabolic clearance might be involved and thus the ability to functionalize this scaffold using “click chemistry” will afford us ample opportunity to improve on this result.

Summary and Outlook. Intense research efforts have been ongoing to discover small molecules that can effectively treat BoNT/A intoxication. Virtually all efforts have centered upon inhibiting enzymatic activity of the neurotoxin, but unfortunately little success has been achieved (6, 8). Our current research has taken an alternative tactic, the use of K^+ channel blockers. The aminopyridines 4-AP and 3,4-DAP have both been shown to be K^+ channel blockers and have provided symptomatic treatment of MS patients (45). However, both 4-AP and 3,4-DAP cross the blood-brain barrier readily, and hence, their potential usefulness has been questioned (46). Capitalizing on crystallographic and modeling data, we were able to identify two new leads for a small molecule K^+ channel inhibitor-based therapeutic approach for the rescue of

BoNT/A intoxicated cells/animals, thus marking the first advancement in this area in almost 20 years. Triaminopyridine **5** proved to be effective in the reversal of BoNT/A-induced muscle paralysis in both phrenic




Figure 4. Rescue of BoNT/A intoxicated mice. The data represents the mean \pm SE ($n = 10$). The differences between all group pairs are statistically significant ($P \leq 0.001$), with the exception of the 3,4-DAP and 5 groups with respect to one another.

nerve-hemidiaphragm preparations and in a mouse toxin neutralization assay; significantly, it showed potency rivaling that of the long-standing benchmark compound 3,4-DAP. Most gratifyingly, this compound's blood-brain barrier entry was restricted, which suggests that this triaminopyridine is likely to exhibit significantly reduced *in vivo* neurotoxicity compared to 3,4-DAP. Lastly, of significant note was pyridinium salt **11**. Although inactive in the mouse lethality study, its potent

efficacy in paralysis reversal as seen in the phrenic nerve-hemidiaphragm assay, coupled with its ability to inhibit K^+ channels, appears to contradict previous studies suggesting that pyridinium salts cannot be utilized as effective K^+ channel blockers. Further advancement of these new leads will pave the way for the development of new small molecule K^+ channel inhibitors for the treatment of BoNT/A poisoning, as well as other neurological disorders.

EXPERIMENTAL SECTION

Materials and Methods. ACS grade organic solvents were purchased from VWR Scientific, and other reagents were obtained from Sigma-Aldrich and used as commercially available. The TLC chromatograms were visualized by UV light and by dipping in potassium permanganate solution followed by heating (hot plate). Final purifications were accomplished by preparative RP-HPLC on a C_{18} -bonded silica column (Vydac 218TP152022, 250 mm \times 22 mm, 15–20 μ m, 300 Å) using a Shimadzu SCL-10A HPLC system. The compounds were eluted with a linear gradient of 1%–10% (v/v) of 0.09% (v/v) TFA/acetonitrile in 0.1% v/v aqueous TFA solution over 40 min with 10 mL min^{-1} flow rate. The purity of the compounds **1–12** was checked by analytical reverse-phase HPLC using a Vydac C_{18} 218TP104 column (Western Analytical Products) monitored at 230 and 254 nm and was determined to be $>95\%$ for all compounds reported herein.

Synthetic Procedures for Compounds 5–12. See the Supporting Information.

Mouse Phrenic Nerve-Hemidiaphragm Assay. Phrenic nerve-hemidiaphragms from mice were incubated (4 $^{\circ}\text{C}$, 45 min) with serotype A botulinum neurotoxin, which along with the serotype C is sensitive to aminopyridine treatment. Then the phrenic nerve-hemidiaphragms were washed and transferred to tissue baths without added toxin. For control tissues, the phrenic nerve was stimulated, and the elapsed time for onset of paralysis was monitored. Experimental tissues were treated identically, except that the bathing medium contained 3,4-DAP or the analogues **5–12**. The paralysis time for control tissues ($n = 10$) was

54 min; that for experimental tissues ($n = 10$) was 102 min, Table 1. A narrow concentration range of 0.3×10^{-4} to 3.3×10^{-4} M was used to produce an enhancement in the muscle twitch response due to nerve stimulation (Table 1). This is a known concentration range reported previously for experiments on reversal of BoNT/A-induced paralysis with 3,4-DAP, while at higher concentrations, there was substantial and sustained depression of muscle responses with 3,4-DAP.

Electrophysiological Studies. *Xenopus laevis* oocytes were isolated and injected with 20 nL of RNase-free water containing 0.5 ng cRNA. Whole-cell currents were measured 1–3 days after injection by the two-electrode voltage clamp technique, using a GeneClamp 500B amplifier (Axon Instruments). Data were sampled at 2 kHz and filtered at 0.5 kHz with Clampex 9.0 software (Axon Instruments). The pipet contained 3 M KCl, and the bath solution contained 4 mM KCl, 96 mM NaCl, 1 mM MgCl_2 , 0.3 mM CaCl_2 , 5 mM HEPES, pH 7.4, with NaOH. Oocyte membrane potential was held at -80 mV, and currents were measured at 0 mV. Currents were measured before and after 30–40 min of incubation in the desired dilution of the tested compound in bath solution. Data points were mean \pm SEM for 5–10 cells (Figure 3). The solid line was a fit of the data to the equation: $I = 1/(1/([C]/K_{0.5})^h)$ where I is the measured current, $[C]$ is the compound concentration, $K_{0.5}$ is the compound concentration required to achieve 50% inhibition, and h is the Hill coefficient. $K_{0.5}$ values were 26.7 ± 4.0 , 697 ± 80 , and 22.2 ± 4.3 μM for 3,4-DAP, **5** and **11**, respectively. The Hill coefficient

was 1.04 ± 0.18 , 1.09 ± 0.13 , and 1.28 ± 0.34 for 3,4-DAP, **5** and **11**, respectively.

Pharmacokinetics and Mouse Brain Penetration. *Compound Administration.* Pharmacokinetic studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals, at a facility whose program is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International. Male CD-1 mice (Charles River) of 25–35 g in weight were divided into six groups of three animals each for measurements at six time points including predose, 0.5, 1.0, 2.0, 4.0, and 8.0 h. This was done for each of the three compounds tested for a total of 54 mice. Each animal was dosed by ip injection at 5.0 mL kg^{-1} with either the saline vehicle (predose) or compound dissolved in vehicle at a dose of 3.0 mg kg^{-1} . Animal groups were sacrificed using carbon dioxide at the described time points followed by removal of blood by cardiac puncture and brain by dissection. Blood was collected in tubes containing heparin, and the plasma separated by centrifugation before being frozen on dry ice. Brains were frozen on dry ice as soon as removed. Pharmacokinetic parameters were calculated using WinNonlin version 5.2 (Pharsight Corporation) from the bioanalytical data (47).

Sample Preparation. The mouse plasma and brain samples were stored at $-20 \text{ }^\circ\text{C}$ until analysis. Mouse plasma samples ($25.0 \text{ }\mu\text{L}$) were transferred into three microcentrifuge tubes (1.7 mL) and mixed with $50 \text{ }\mu\text{L}$ of internal standard solution (200 ng mL^{-1} of **11** in acetonitrile for **3** and **5**; 200 ng mL^{-1} of **5** in acetonitrile for **11**). The tubes were vortex mixed for 1 min and centrifuged at $10,000g$ for 4 min. A $50 \text{ }\mu\text{L}$ sample of the supernatant was transferred into an autosampler vial and mixed with 50 or $150 \text{ }\mu\text{L}$ (for **3**) of water.

Each of the mouse brain samples was first homogenized with 3.0 mL of 25% acetonitrile in water. Mouse brain homogenate samples ($50.0 \text{ }\mu\text{L}$) were transferred into microcentrifuge tubes (1.7 mL) and mixed with $100 \text{ }\mu\text{L}$ of internal standard solution (200 ng mL^{-1} of **11** in acetonitrile for **5** and **3**; 200 ng mL^{-1} of **5** in acetonitrile for **11**). The tubes were vortex mixed for 1 min and centrifuged at $10,000g$ for 5 min. An aliquot of the supernatant ($50.0 \text{ }\mu\text{L}$) was transferred into an autosampler vial and mixed with $50 \text{ }\mu\text{L}$ (for **11**) and $150 \text{ }\mu\text{L}$ (for **3**) water or $100 \text{ }\mu\text{L}$ of 50% acetonitrile (for **5** brain homogenate) for LC/MS/MS analysis.

Chromatography. The LC/MS/MS analyses were performed on an Agilent 1100 Binary Pump HPLC system equipped with a Sciex API 3000 mass spectrometer (compound **3**) or a Shimadzu LC-20AD system with a Sciex API 5000 mass spectrometer (compounds **5** and **11**), using a Polaris C-18, $3 \text{ }\mu\text{m}$, $50 \text{ mm} \times 3.0 \text{ mm}$ HPLC column. Formic acid (0.1%) and 45% methanol–45% acetonitrile in water were used as solvents A and B, respectively, with the following gradient: (0 min) 30% B, (0.1 min) 100% B, (2.9 min) 100% B, (3.0 min) 30% B, (6.0 min) 30% B; flow rate of $200 \text{ }\mu\text{L min}^{-1}$.

Preparation of Quality Control and Calibration Samples. Quality control samples and calibration samples were prepared by spiking blank mouse plasma and brain homogenate (from control animal of this study) with working solutions prepared from a single weighing. The standard samples were prepared in the following dilutions: 0.500, 1.00, 2.500, 5.00, 10.0, 25.0, 50.0, 100, 250, 500 ng mL^{-1} , and the QC samples used 0.500, 5.00, 50.0, 500 ng mL^{-1} concentrations for the plasma samples and 2.50, 25.0, 250 ng mL^{-1} concentrations for the brain tissue samples. The calibration curves were weighed by $1/\chi^2$ using a linear regression without being forced through the origin.

Sensitivity and Linearity of the Method. The lower limits of quantitation (LLOQ) for **3**, **5**, and **11** were determined to be 1.000, 0.500, and 0.500 ng mL^{-1} , respectively, in plasma; 1.000, 1.000, and 0.500 ng mL^{-1} , respectively, in brain homogenate; and 6.000, 6.000, and 3.000 ng mL^{-1} , respectively, in brain tissue. The calibration curves were linear in the above prepared concentration ranges.

BoNT/A Mouse Lethality Assay. The *C. botulinum* type A neurotoxin was prepared and purified as previously described (48). Female CD-1 outbred mice (17–23 g; Harlan Sprague-Dawley, Madison, WI) animals that were included in the toxin challenge group were injected with 0.5 mL of a solution of neurotoxin containing $10 \text{ ip LD}_{50} \text{ mL}^{-1}$. At the first signs of BoNT distress (120 min) the K^+ channel blockers were administered ip and subsequently every 75 min for a total of 5 injections. Control animals did not receive toxin challenge. Animals were observed for signs of botulism, and the time of death in minutes was recorded.

Acknowledgment: The authors gratefully acknowledge W. Metz of Sanofi-Aventis for his role in bridging support between the research groups and A. Moreno of TSRI for her expert assistance in HPLC analysis of the reported compounds. Support of this project was partially provided by the National Institute of Allergy and Infectious Diseases AI080671.

Supporting Information Available: This material is available free of charge via the Internet at <http://pubs.acs.org>.

REFERENCES

- Johnson, E. A., and Bradshaw, M. (2001) *Clostridium botulinum* and its neurotoxins: a metabolic and cellular perspective, *Toxicol* **39**, 1703–1722.
- Singh, B. R. (2000) Intimate details of the most poisonous poison, *Nat. Struct. Biol.* **7**, 617–619.
- Schantz, E. J., and Johnson, E. A. (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine, *Microbiol. Mol. Biol. Rev.* **56**, 80–99.
- Amon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M. T., O'Toole, T., Parker, G., Perl, T. M., Russell, P. K., Swerdlow, D. L., and Tonat, K. (2001) Botulinum toxin as a biological weapon: medical and public health management, *J. Am. Med. Assoc.* **285**, 1059–1070.
- Osborne, S. L., Latham, C. F., Wen, P. J., Cavaignac, S., Fanning, J., Foran, P. G., and Meunier, F. A. (2007) The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon, *J. Neurosci. Res.* **85**, 1149–1158.
- Willis, B., Eubanks, J., Lisa, M., Dickerson, Tobin J., and Janda, Kim D. (2008) The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison, *Angew. Chem., Int. Ed.* **47**, 8360–8379.
- Simpson, L. L. (2004) Identification of the major steps in botulinum toxin action, *Annu. Rev. Pharmacol. Toxicol.* **44**, 167–193.
- Dickerson, T. J., and Janda, K. D. (2006) The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication, *ACS Chem. Biol.* **1**, 359–369.
- Lundh, H., Cull-Candy, S. G., Leander, S., and Thesleff, S. (1976) Restoration of transmitter release in botulinum-poisoned skeletal muscle, *Brain Res.* **110**, 194–198.
- Lundh, H., Leander, S., and Thesleff, S. (1977) Antagonism of the paralysis produced by botulinum toxin in the rat: The effects of tetraethylammonium, guanidine and 4-aminopyridine, *J. Neuro. Sci.* **32**, 29–43.
- Metzeau, P., and Desban, M. (1982) Botulinum toxin type A: kinetics of calcium dependent paralysis of the neuromuscular junction and antagonism by drugs and animal toxins, *Toxicol* **20**, 649–654.
- Molgo, J., Lemeignan, M., Lechat, P., and Peradejordi, F. (1985) Increase in evoked transmitter release from motor nerve terminals by some amino N-heterocyclic compounds. I. Comparative experimental activities and extracellular pH-dependence, *Eur. J. Med. Chem.* **20**, 149–153.

13. Adler, M., Scovill, J., Parker, G., Lebeda, F. J., Piotrowski, J., and Deshpande, S. S. (1995) Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations, *Toxicon* 33, 527–537.
14. Doc, M., Ali, A. B., Karras, A., Misset, B., Garrouste-Orgeas, M., Deletie, E., Goldstein, F., and Carlet, J. (2002) Treatment of severe botulism with 3,4-diaminopyridine, *Presse Med.* 31, 601–602.
15. Davis, L. E., Johnson, J. K., Bicknell, J. M., Levy, H., and McEvoy, K. M. (1992) Human type A botulism and treatment with 3,4-diaminopyridine, *Electromyogr. Clin. Neurophysiol.* 32, 379–383.
16. Adler, M., Sheridan, R. E., Manley, H. A., Manley, A., Aplan, J., Deshpande, S. S., Romano, J. (2004) Development of treatments for intoxication by botulinum neurotoxin, in *Pharmacological Perspectives of Toxic Chemicals and Their Antidotes* (Flora, S. J. S., Romano, J. A., Baskin, S. I., and Sekhar, K., Eds.), pp 359–381, Narosa Publishing House, New Delhi, India.
17. Carlsson, C., Rosen, I., and Nilsson, E. (1993) Can 4-aminopyridine be used to reverse anaesthesia and muscle relaxation? *Acta Anaesthesiol. Scand.* 27, 87–90.
18. Schwid, S. R., Petrie, M. D., McDermott, M. P., Tierney, D. S., Maso, D. H., and Goodman, A. D. (1997) Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis, *Neurology* 48, 817–821.
19. McEvoy, K. M., Windebank, A. J., Daube, J. R., and Low, P. A. (1989) 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome, *N. Engl. J. Med.* 321, 1567–1571.
20. Davidson, M., Zemishlany, Z., Mohs, R. C., Horvath, T. B., Powchik, P., Blass, J. P., and Davis, K. L. (1988) 4-Aminopyridine in the treatment of Alzheimer's disease, *Biol. Psychiatry* 23, 485–490.
21. Uchiyama, T., Lemeignan, M., and Lechat, P. (1985) Equipotency of anti-curare activity of 4-aminopyridine and 3,4-diaminopyridine in anesthetized rats, *Jpn. J. Pharmacol.* 38, 329–333.
22. Plewa, M., Martin, T., Menegazzi, J., Seaberg, D., and Wolfson, A. (1994) Hemodynamic effects of 3,4-diaminopyridine in a swine model of verapamil toxicity, *Ann. Emerg. Med.* 23, 499–507.
23. Damsma, G., Biessels, P. T. M., Westerink, B. H. C., De Vries, J. B., and Horn, A. S. (1988) Differential effects of 4-aminopyridine and 2,4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis, *Eur. J. Pharmacol.* 145, 15–20.
24. Nino, A., and Munoz-Caro, C. (2001) Theoretical analysis of the molecular determinants responsible for the K⁺ channel blocking by aminopyridines, *Biophys. Chem.* 91, 49–60.
25. Munoz-Caro, C., and Nino, A. (2002) The nature of the receptor site for the reversible K⁺ channel blocking by aminopyridines, *Biophys. Chem.* 96, 1–14.
26. Nino, A., Munoz-Caro, C., Carbo-Dorca, R., and Girones, X. (2003) Rational modelling of the voltage-dependent K⁺ channel inactivation by aminopyridines, *Biophys. Chem.* 104, 417–427.
27. Lippiat, J. D., Standen, N. B., and Davies, N. W. (2000) A residue in the intracellular vestibule of the pore is critical for gating and permeation in Ca²⁺-activated K⁺ (BK_{Ca}) channels, *J. Physiol.* 529, 131–138.
28. Choquet, D., and Korn, H. (1992) Mechanism of 4-aminopyridine action on voltage-gated potassium channels in lymphocytes, *J. Gen. Physiol.* 99, 217–240.
29. Caballero, N. A., Meléndez, F. J., Niño, A., and Muñoz-Caro, C. (2007) Molecular docking study of the binding of aminopyridines within the K⁺ channel, *J. Mol. Model.* 13, 579–586.
30. Mohajer, D., Karimipour, G., and Bagherzadeh, M. (2004) Reactivity studies of biomimetic catalytic epoxidation of alkenes with tetrabutylammonium periodate in the presence of various manganese porphyrins and nitrogen donors: significant axial ligand π -bonding effects, *New Journal of Chemistry* 28, 740–747.
31. Kolb, H. C., and Sharpless, K. B. (2003) The growing impact of click chemistry on drug discovery, *Drug Discovery Today* 8, 1128–1137.
32. Graboyes, H., and Day, A. R. (1957) Metabolite analogs. VIII. Syntheses of some imidazopyridines and pyridotriazoles, *J. Am. Chem. Soc.* 79, 6421–6426.
33. Burton, A. G., Frampton, R. D., Johnson, C. D., and Katritzky, A. R. (1972) The kinetics and mechanism of the electrophilic substitution of heteroaromatic compounds. Part XXVIII. The preparation and kinetic nitration of 2-, 3-, and 4-dimethylaminopyridines and their 1-oxides in sulphuric acid, *J. Chem. Soc., Perkin Trans. 2* 1940–1949.
34. Jiao, Y., and Yu, H. (2001) Methyltrioxorhenium (MeReO₃) catalyzed selective oxidation of purine and related compounds into their N-oxides, *Synlett* 1, 73–74.
35. Clark-Lewis, J. W., and Singh, R. P. (1962) 459. Preparation of 3,4-diamino-, 3-amino-4-methylamino-, and 4-amino-3-methylaminopyridine, *J. Chem. Soc.* 2379–2382.
36. Essery, J. M., and Schofield, K. (1960) 961. Some derivatives of 4-amino- and 4-nitro-pyridine, *J. Chem. Soc.* 4953–4959.
37. Vohra, M. M., Pradhan, S. N., Jain, P. C., Chatterjee, S. K., and Anand, N. (1965) Synthesis and structure-activity relationships of some aminopyridines, imidazopyridines, and triazolopyridines, *J. Med. Chem.* 8, 296–304.
38. Singh, S., Das, G., Singh, O. V., and Han, H. (2007) Development of more potent 4-dimethylaminopyridine analogues, *Org. Lett.* 9, 401–404.
39. Simpson, L. L. (1974) Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation, *Neuropharmacology* 13, 683–691.
40. Simpson, L. (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction, *J. Pharmacol. Exp. Ther.* 212, 16–21.
41. Lopez-Barneo, J., Hoshi, T., Heinemann, S. H., and Aldrich, R. W. (1993) Effects of external cations and mutations in the pore region on C-type inactivation of *Shaker* potassium channels, *Recept. Channels* 1, 61–71.
42. Claydon, T. W., Vaid, M., Rezaazadeh, S., Kehl, S. J., and Fedida, D. (2007) 4-Aminopyridine prevents the conformational changes associated with P/C-Type inactivation in *Shaker* channels, *J. Pharmacol. Exp. Ther.* 320, 162–172.
43. Kozminsky-Atias, A., Somech, E., and Zilberberg, N. (2007) Isolation of the first toxin from the scorpion *Buthus occitanus israelis* showing preference for *Shaker* potassium channels, *FEBS Lett.* 581, 2478–2484.
44. Baud, F. J., Megarbane, B., and Deye, N. (2008) 4-Aminopyridine derivatives for calcium channel blocker poisonings, *Clin. Toxicol.* 46, 356.
45. Bever, C. T., Leslie, J., Camenga, D. L., Panitch, H. S., and Johnson, K. P. (1990) Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis, *Ann. Neurol.* 27, 421–427.
46. Judge, S. I. V., and Bever, C. T. (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment, *Pharmacol. Ther.* 111, 224–259.
47. Gabrielsson, J., Weiner, D. (2001) *Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications*, 4th ed., Swedish Pharmaceutical Press, Stockholm, Sweden.
48. Eubanks, L. M., Hixon, M. S., Jin, W., Hong, S., Clancy, C. M., Tepp, W. H., Baldwin, M. R., Malizio, C. J., Goodnough, M. C., Barbieri, J. T., Johnson, E. A., Boger, D. L., Dickerson, T. J., and Janda, K. D. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists, *Proc. Natl. Acad. Sci. U.S.A.* 104, 2602–2607.